Related Experiment Video
Updated: May 18, 2026

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
Published on: July 19, 2024
Metabolic Dysfunction-Associated Steatotic Liver Disease: Global Epidemiology, Patient-Reported Outcomes, and
James M Paik1, Linda Henry2, Khalid AlNaamani3
1The Global NASH/MASH Council (GNC), Washington DC, USA; The Global Center for Liver Outcomes and Policy Research Georgetown University School of Medicine, Washington, DC, USA.
None:
In 2023, new terminology [metabolic dysfunction associated steatotic liver disease (MASLD)] was introduced adressing the shortfalls (stigma/underreporting of alcohol) of nonalcoholic fatty liver disease (NAFLD). MASLD falls within a SLD spectrum dependent upon cardio-metabolic risk factors (CMRFs) and alcohol consumption [MASLD (< 20 g females/30 g males), MetALD (<50g females/<60 g males), and ALD (≥ 50g females/ ≥ 60 g males). HRQL, economic burden, fibrosis, cirrhosis, cancer, and mortality are inversely related with alcohol and presence of multiple CMRFs. Adult prevalence rates of MASLD, Met-ALD and ALD are 30%+, 2.2%-10%, and 1%-3%, respectively. Increased awareness of SLD and decreasing alcohol consumption interventions are needed.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Cirrhosis I: Introduction
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Cirrhosis II: Pathophysiology

